“hepatitis”的搜索结果，显示 201-210 项，共有 11958 项

1. 血液科- 临床试验- 妙佑医疗国际

   The purpose of this study is to evaluate the safety and tolerability, identify dose-limiting toxicities (DLT) and the maximum tolerated dose (MTD and ...

2. 血液科- 临床试验- 妙佑医疗国际

   Scottsdale/Phoenix, Ariz., Rochester, Minn. This is a peripheral blood Collection Protocol to study the T-cell immune responses of patients with malignancies ...

3. 肝纤维化- 症状与病因- 妙佑医疗国际

   Gastroenterology Report. 2024; doi:10.1093/gastro/goae024. Zhao L, et al. Pharmacotherapy of liver fibrosis and hepatitis: Recent advances. Pharmaceuticals.

4. 血液科- 临床试验- 妙佑医疗国际

   The purpose of this study is to develop and maintain a registry of clinical data and biological specimens from patients with immune system related blood ...

5. 胃肠病科和肝病科- 临床试验- 妙佑医疗国际

   Rochester, Minn. About this study. Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the world and a major public ...

6. 血液科- 临床试验- 妙佑医疗国际

   Rochester, Minn. The purpose of this study is to determine if the drug combination of acalabrutinib, durvalumab, and venetoclax will work to treat Richter's ...

7. 血液科- 临床试验- 妙佑医疗国际

   Rochester, Minn. The purpose of this study is to determine if the drug combination of acalabrutinib, durvalumab, and venetoclax will work to treat Richter's ...

8. 血液科- 临床试验- 妙佑医疗国际

   Rochester, Minn. The purpose of this study is to determine if the drug combination of acalabrutinib, durvalumab, and venetoclax will work to treat Richter's ...

9. 血液科- 临床试验- 妙佑医疗国际

   Rochester, Minn. The purpose of this study is to determine if the drug combination of acalabrutinib, durvalumab, and venetoclax will work to treat Richter's ...

10. 血液科- 临床试验- 妙佑医疗国际

    This phase III trial compares the effect of high dose chemotherapy and the patients' own (autologous) stem cells to observation only in patients with ...